Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director | March 31, 2022 | April 04, 2022 |
| MILESTONE SCIENTIFIC INC.MLSS · Entity 7313 | President and CEO | August 18, 2017 | August 21, 2017 |
| Xtant Medical Holdings, Inc.XTNT · Entity 7196 | Director · Chief Executive Officer | November 14, 2016 | November 25, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KORU Medical Systems, Inc.
Report date March 31, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,334 |
Reported balance
After 2022-03-31 transaction · row 1
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 5,221 · Balance 120,334 |
MILESTONE SCIENTIFIC INC.
Report date August 18, 2017 · Filed August 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2017-08-18 transaction · row 1
1 source rowRow 1 · 2017-08-18 · Purchase · Acquired 5,000 · Balance 10,000 F1: Reflects the weighted average price of multiple same day open market purchases within a one dollar price range of one another at prices ranging from $1.131 to $1.150 per share. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2022-07-10 | Direct | 921,942 |
Reported balance
Holding disclosure · report date 2017-08-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 921,942 F2: These options are exercisable beginning on 7/10/18 with respect to one-third of the shares of common stock and for an additional one-third on each of 7/10/19 and 7/10/20, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the weighted average price of multiple same day open market purchases within a one dollar price range of one another at prices ranging from $1.131 to $1.150 per share.
F2: These options are exercisable beginning on 7/10/18 with respect to one-third of the shares of common stock and for an additional one-third on each of 7/10/19 and 7/10/20, respectively.
Xtant Medical Holdings, Inc.
Report date November 14, 2016 · Filed November 25, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 135,510 |
Reported balance
After 2016-11-17 transaction · row 1
1 source rowRow 1 · 2016-11-17 · Other · Acquired 120,000 · Balance 135,510 F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. |
| Subscription Rights (right to receive)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2016-11-14 | Direct | 0 |
Reported balance
After 2016-11-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-14 · Other · Disposed 120,000 · Balance 0 F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2021-11-17 | Direct | 120,000 |
Reported balance
After 2016-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-17 · Other · Acquired 120,000 · Balance 120,000 F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. F2: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.90 from the date of issuance through November 17, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 86,522 |
Reported balance
Holding disclosure · report date 2016-11-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 86,522 |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75.
F2: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.90 from the date of issuance through November 17, 2021.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
electroCore, Inc.
Report date April 23, 2026 · Filed June 12, 2026
Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 211,471 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Sale · Disposed 80,000 · Balance 211,471 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $8.52 per share between 04/23/26 and 05/26/26 subject to Rule 144. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by him at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $8.52 per share between 04/23/26 and 05/26/26 subject to Rule 144. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by him at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2019 Filed Jun 17, 2019 20:22 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 500 | $2.21 | $1,105.00 |
DisclosureSEC source: 0001161697-19-000244 · form_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,922 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:36 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 90,604 | $1.49 | $134,999.96 |
DisclosureSEC source: 0001161697-19-000137 · form_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,422 F1 · shares: Per Mr. Goldberger's employment agreement dated October 12, 2018, on April 1, 2019, Mr. Goldberger was paid a performance bonus equaling 50% of the initial annual base salary, plus 50% of the initial target bonus, payable to the person who first succeeded Mr. Goldberger as chief executive officer of the company. In accordance with the terms of the agreement and as approved by the Board of Directors, the bonus was paid half in cash and half in shares of common stock. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 23:30 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 226 | $1.65 | $372.90 |
DisclosureSEC source: 0001161697-19-000008 · form_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director · Chairman and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 21:30 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantOption to Purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001161697-18-000492 · form_4.xml · derivative · entry 2 Goldberger Daniel S · CIK 0001382042 · Director · Chairman and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: REPRO MED SYSTEMS, INC. d/b/a RMS Medical Products (the "Company") entered into an employment agreement with Mr. Goldberger on October 12, 2018 and as part of his employment agreement he was awarded these non-qualified stock options on the same date under the Company's 2015 Stock Option Plan, as amended. 100,000 of the options shall vest immediately and 25,000 of the options shall vest per completed quarter until fully vested, subject to acceleration in accordance with the terms of the award agreement. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 22:02 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 1,894 | $1.65 | $3,125.10 |
DisclosureSEC source: 0001161697-18-000466 · form_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director · Chairman and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,592 Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:43 UTC | KORU Medical Systems, Inc. REPR · Entity 6517 | GrantCommon Stock | 1,698 | $1.38 | $2,343.24 |
DisclosureSEC source: 0001161697-18-000349 · form_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,698 Read SEC document |
| August 18, 2017 Filed Aug 21, 2017 20:06 UTC | MILESTONE SCIENTIFIC INC. MLSS · Entity 7313 | PurchaseCommon Stock, $0.001 par value | 5,000 | $1.14 | $5,705.00 |
DisclosureSEC source: 0001437749-17-015106 · rdgdoc.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Reflects the weighted average price of multiple same day open market purchases within a one dollar price range of one another at prices ranging from $1.131 to $1.150 per share. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 19:18 UTC | MILESTONE SCIENTIFIC INC. MLSS · Entity 7313 | PurchaseCommon Stock, $.001 par value | 5,000 | $1.14 | $5,715.00 |
DisclosureSEC source: 0001437749-17-015029 · rdgdoc.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 20:37 UTC | MILESTONE SCIENTIFIC INC. MLSS · Entity 7313 | GrantOptions to purchase common stock · Derivative | 921,942 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001437749-17-012512 · rdgdoc.xml · derivative · entry 1 Goldberger Daniel S · CIK 0001382042 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,942 Underlying: Common Stock · 921,942 shares Expires 2022-07-10 F2 · price: Not applicable. F1 · derivative.exercise_date: These options are exercisable beginning on 7/10/18 with respect to one-third of the shares of common stock and for an additional one-third on each of 7/10/19 and 7/10/20, respectively. Read SEC document |
| November 17, 2016 Filed Nov 25, 2016 20:15 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | OtherWarrants (right to buy) · Derivative | 120,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001144204-16-136550 · v453905_4.xml · derivative · entry 4 Goldberger Daniel S · CIK 0001382042 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2021-11-17 F1 · price: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. F2 · derivative.underlying: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.90 from the date of issuance through November 17, 2021. Read SEC document |
| November 17, 2016 Filed Nov 25, 2016 20:15 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | OtherCommon Stock | 120,000 | $0.75 | $90,000.00 |
DisclosureSEC source: 0001144204-16-136550 · v453905_4.xml · nonDerivative · entry 1 Goldberger Daniel S · CIK 0001382042 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,510 F1 · price: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. Read SEC document |
| November 14, 2016 Filed Nov 25, 2016 20:15 UTC | Xtant Medical Holdings, Inc. XTNT · Entity 7196 | OtherSubscription Rights (right to receive) · Derivative | 120,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001144204-16-136550 · v453905_4.xml · derivative · entry 3 Goldberger Daniel S · CIK 0001382042 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: See footnote · 120,000 shares Expires 2016-11-14 F1 · derivative.underlying: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock and outstanding convertible notes. Each holder received 2 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription price per unit was $0.75. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.